Current NHS Access to Retatrutide
Retatrutide is not available through the NHS as of May 2026. NHS access to new obesity drugs follows a specific process: the drug must receive MHRA approval, then NICE must evaluate its cost-effectiveness and issue guidance, and finally NHS England must make it available. This process typically takes 1 to 3 years after regulatory approval. For context, semaglutide received FDA approval in 2021 but was not widely available on the NHS until 2023. Retatrutide, which is not yet approved by any regulatory body, is years away from NHS availability.
The NICE Process
NICE evaluates new drugs based on their cost-effectiveness using a metric called the quality-adjusted life year. Drugs that cost more than £20,000 to £30,000 per QALY gained are less likely to be recommended. Given that retatrutide is expected to be priced at -1,200 per month if approved in the US, and UK prices are typically similar, the drug will need to demonstrate exceptional efficacy to meet NICE thresholds. The 28-30% weight loss seen in the TRIUMPH trials will help, but NICE will also consider the long-term health benefits and cost savings from reduced obesity-related complications.
How to Access Retatrutide in the UK Currently
Private clinics in the UK sometimes offer early access to new drugs through specialist prescribing, but this requires MHRA approval first. Until then, the only options are grey market research vendors. UK-based vendors sell retatrutide as a research chemical for approximately £50-100 per 10 mg vial. The MHRA has issued warnings about the risks of buying unlicensed medicines online, and individuals who choose this route should be aware that they are purchasing products without the safety guarantees that come with regulated pharmaceuticals.
Leave a Reply